TRAC Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| MT-2765 | MT-2765 | Phase 3 Clinical | Mitsubishi Tanabe Pharma Corp | Hypertension | Details |
| SP-20104 (Sarfez Pharmaceuticals) | SP-20104 | Phase 2 Clinical | 1 A Pharma Gmbh | Glomerulosclerosis, Focal Segmental | Details |
| Imarikiren hydrochloride | TAK-272; SCO-272 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Kidney Diseases; Hypertension; Diabetic Nephropathies; Hepatic Insufficiency | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Aliskiren Hemifumarate/Amlodipine Besilate/Hydrochlorothiazide | Approved | Novartis Pharma Ag | Rasitrio, Amturnide | United States | Hypertension | null | 2010-12-21 | Hypertension; Essential Hypertension | Details | |
| Aliskiren Hemifumarate | SPP-100; SPP-100A; SPP-100B; CGP-60536; CGP-60536B | Approved | Novartis Pharma Ag | Enviage, Rasilez, Riprazo, Sprimeo, Tekturna, 锐思力 | United States | Hypertension | Noden Pharma Dac | 2007-03-05 | Myocardial Ischemia; Heart Failure; Myocardial Infarction; Diabetes Mellitus, Type 2; Glomerulonephritis, IGA; Coronary Artery Disease; Hypertension; Hypertrophy, Left Ventricular; Diabetic macular oedema; Cardiovascular Diseases; Diabetic Nephropathies; Essential Hypertension; Overweight; Diabetes Mellitus; Kidney Failure, Chronic | Details |
| Aliskiren | Approved | Mainland China | Essential Hypertension | Novartis Pharma Ag | 2010-03-26 | Essential Hypertension | Details |